Abstract
High-dose therapy (HDT) followed by autologous stem cell transplantation (ASCT) remains the standard of care for patients younger than 65 years of age with multiple myeloma (MM). However, this therapeutic approach has undergone substantial advances in this last decade, mainly due to the introduction of new drugs such as thalidomide, lenalidomide and bortezomib. These new drugs, in different combinations, have shown to significantly increase response rates after induction therapy and ASCT. Moreover, the positive results obtained with these agents in consolidation and maintenance strategies after ASCT strongly support the concept of continuous therapy, whose ultimate goal is the long-term control of the disease and the improvement of outcome. Preliminary data from studies investigating next generation proteasome inhibitors, such as carfilzomib and ixazomib, used upfront as well as at subsequent therapeutic lines, demonstrate the possibility of achieving molecular remission in most of the patients. The deeper responses obtained with new drugcombinations questioned the role of ASCT, and large, ongoing, phase 3 trials will shed light on the role and the timing of ASCT.
Keywords: Stem cell transplantation, multiple myeloma, ASCT, proteasome inhibitors, carfilzomib, ixazomib.
Current Cancer Drug Targets
Title:Stem Cell Transplantation in Multiple Myeloma
Volume: 17 Issue: 9
Author(s): Massimo Offidani, Silvia Gentili, Francesca Gay, Elena Aghemo, Laura Maracci, Laura Corvatta and Antonio Palumbo*
Affiliation:
- Division of Hematology, University of Torino, Via Genova 3, 10126 Torino,Italy
Keywords: Stem cell transplantation, multiple myeloma, ASCT, proteasome inhibitors, carfilzomib, ixazomib.
Abstract: High-dose therapy (HDT) followed by autologous stem cell transplantation (ASCT) remains the standard of care for patients younger than 65 years of age with multiple myeloma (MM). However, this therapeutic approach has undergone substantial advances in this last decade, mainly due to the introduction of new drugs such as thalidomide, lenalidomide and bortezomib. These new drugs, in different combinations, have shown to significantly increase response rates after induction therapy and ASCT. Moreover, the positive results obtained with these agents in consolidation and maintenance strategies after ASCT strongly support the concept of continuous therapy, whose ultimate goal is the long-term control of the disease and the improvement of outcome. Preliminary data from studies investigating next generation proteasome inhibitors, such as carfilzomib and ixazomib, used upfront as well as at subsequent therapeutic lines, demonstrate the possibility of achieving molecular remission in most of the patients. The deeper responses obtained with new drugcombinations questioned the role of ASCT, and large, ongoing, phase 3 trials will shed light on the role and the timing of ASCT.
Export Options
About this article
Cite this article as:
Offidani Massimo, Gentili Silvia, Gay Francesca , Aghemo Elena, Maracci Laura, Corvatta Laura and Palumbo Antonio*, Stem Cell Transplantation in Multiple Myeloma, Current Cancer Drug Targets 2017; 17 (9) . https://dx.doi.org/10.2174/1568009616666160920090236
DOI https://dx.doi.org/10.2174/1568009616666160920090236 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Innovative Cancer Drug Targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
"Old Friends in New Guise": Exploiting Privileged Structures for Scaffold Re-Evolution/Refining
Combinatorial Chemistry & High Throughput Screening Removal of the Tag from His-tagged ILYd4, a Human CD59 Inhibitor, Significantly Improves its Physical Properties and its Activity
Current Pharmaceutical Design Potential Therapeutic Targets for Steroid-Resistant Asthma
Current Drug Targets The Cell-Type Specificity and Endosomal Escape of Cell-Penetrating Peptides
Current Pharmaceutical Design Recent Approaches on Novel Topical Delivery Systems for Atopic Dermatitis Treatment
Recent Patents on Drug Delivery & Formulation Chronic Eosinophilic Leukemia, Not Otherwise Specified (CEL, NOS)
Current Cancer Therapy Reviews Immunohistochemical and Serological 90K / Mac-2BP Detection in Hepatocellular Carcinoma Patients: Different Behaviour of Two Monoclonal Antibodies
Medicinal Chemistry Thioethers: An Overview
Current Drug Targets MicroRNA-21: From Cancer to Cardiovascular Disease
Current Drug Targets Podophyllotoxin: Current Perspectives
Current Bioactive Compounds Anti-tumor Therapeutic Molecules that Target the Programmed Cell Death Machinery
Mini-Reviews in Medicinal Chemistry Zevalin™: 90Yttrium Labeled Anti-CD20 (Ibritumomab Tiuxetan), a New Treatment for Non-Hodgkin ’ s Lymphoma
Current Pharmaceutical Biotechnology On the Nature of the Tumor-Initiating Cell
Current Stem Cell Research & Therapy A Review on PARP1 Inhibitors: Pharmacophore Modeling, Virtual and Biological Screening Studies to Identify Novel PARP1 Inhibitors
Current Topics in Medicinal Chemistry ADMET Profiling in Drug Discovery and Development: Perspectives of In Silico, In Vitro and Integrated Approaches
Current Drug Metabolism Predictive Biomarkers to Tyrosine Kinase Inhibitors for the Epidermal Growth Factor Receptor in Non-Small-Cell Lung Cancer
Current Drug Targets New Antihypertensive Drugs Under Development
Current Medicinal Chemistry Synthetic Approaches to Various Class of Topoisomerase II Inhibitors
Mini-Reviews in Organic Chemistry Fungal Gene-Encoded Peptidase Inhibitors
Current Medicinal Chemistry Antibody-Drug Conjugate Targets
Current Cancer Drug Targets